Renalytix PLC
LSE:RENX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Swan Energy Ltd
NSE:SWANENERGY
|
IN |
|
Keihanshin Building Co Ltd
TSE:8818
|
JP |
|
Wolverine World Wide Inc
NYSE:WWW
|
US |
|
Aquis Exchange PLC
LSE:AQX
|
UK |
|
Volkswagen AG
XETRA:VOW
|
DE |
|
I
|
Insig Ai PLC
LSE:INSG
|
UK |
Renalytix PLC
Research & Development
Renalytix PLC
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Renalytix PLC
LSE:RENX
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Craneware PLC
LSE:CRW
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cambridge Cognition Holdings PLC
LSE:COG
|
Research & Development
-£2.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Feedback PLC
LSE:FDBK
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Doctor Care Anywhere Group PLC
ASX:DOC
|
Research & Development
-£3.7m
|
CAGR 3-Years
20%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
P
|
Physitrack PLC
STO:PTRK
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Renalytix PLC
Glance View
Renalytix Plc manufactures medical devices and equipment. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2018-11-06. The firm is focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care. The firm's diagnostic platform, KidneyIntelX, is designed to scale across kidney disease conditions beyond diabetic kidney disease. The firm is evaluating a range of new indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and coronavirus disease (COVID)-related kidney disease. KidneyIntelX platform facilitates the identification and promotes the effective management of patients at risk of early-stage diabetic kidney disease (DKD), progression by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record (HER) using a proprietary algorithm to generate a unique patient risk score.
